Akero Therapeutics Inc. (AKRO)
45.07
-0.15 (-0.33%)
At close: Mar 24, 2025, 3:59 PM
44.50
-1.26%
Pre-market: Mar 25, 2025, 04:33 AM EDT
-0.33% (1D)
| Bid | 40 |
| Market Cap | 3.59B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -284.37M |
| EPS (ttm) | -3.75 |
| PE Ratio (ttm) | -12.02 |
| Forward PE | -10.69 |
| Analyst | Strong Buy |
| Ask | 49.5 |
| Volume | 508,560 |
| Avg. Volume (20D) | 1,353,750 |
| Open | 45.12 |
| Previous Close | 45.22 |
| Day's Range | 44.61 - 46.14 |
| 52-Week Range | 17.86 - 58.40 |
| Beta | -0.20 |
About AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2019
Employees 63
Stock Exchange NASDAQ
Ticker Symbol AKRO
Website https://www.akerotx.com
Analyst Forecast
According to 9 analyst ratings, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $75, which is an increase of 66.41% from the latest price.
Stock Forecasts1 month ago
+97.52%
Akero Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
